Latest Daily News

More Stories

May 16, 2018

ASCO recently released a new Clinical Practice Guideline on the management of malignant pleural mesothelioma.

Read more

May 14, 2018

When we were asked to write an Expert Editorial about smoking cessation in patients with cancer, our first thought was, isn’t this topic settled and already well understood?

Read more

May 14, 2018

By 2030, the number of deaths due to lung cancer is expected to almost double for Latin American women and increase by 50% for Latin American men.

Read more

May 14, 2018

The therapeutic landscape of advanced non–small cell lung cancer (NSCLC) has seen a rapid shift in the last 2 years with the introduction of immunotherapy into treatment algorithms.

Read more

May 11, 2018

Nagashree Seetharamu, MD, MBBS, answers a question posed by an attendee at a Best of ASCO® Meeting.

Read more

June 6, 2017

Researchers presented results of four studies evaluating new approaches to targeted therapies for patients with lung cancer, including metastatic non–small cell lung cancer.

Read more
June 5, 2017

Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.

Read more
June 5, 2017

The EGFR tyrosine-kinase inhibitor gefitinib appears to offer a disease-free survival benefit over vinorelbine/cisplatin as adjuvant therapy in patients with non–small cell lung cancer with EGFR-activating mutation.

Read more

June 3, 2017

Presenters discussed current concepts regarding the treatment of early-stage disease, along with efforts to better enhance local control.

Read more
June 2, 2017

Researchers overseeing the trial at Roswell Park discuss the effectiveness of CIMAvax-EGF in NSCLC, the results of completed clinical trials in Cuba, and the long-term plans for additional testing of the vaccine.

Read more
May 25, 2017

Smoking not only causes many forms of cancer, but continued smoking by people with cancer and cancer survivors causes adverse health outcomes, including increased overall mortality, cancer-specific mortality, and risk for second primary cancer and is associated with increased treatment toxicity.

Read more
May 25, 2017

During the Education Session “Tobacco Cessation and CT Screening Recommendations for Patients With Lung Cancer,” to be held on June 4, experts will discuss strategies for implementing lung cancer screening programs.

Read more
May 25, 2017

How to best manage issues that are common in older patients with advanced non–small cell lung cancer will be the focus of the Education Session “Lung Cancer in the Older Population: Caring for the Whole Patient."

Read more
May 25, 2017

This editorial discusses the role of RET rearrangements in non–small cell lung cancer (NSCLC) and the latest advances in RET fusion–targeting approaches.

Read more
April 7, 2017

Vamsidhar Velcheti, MD, and his team have been investigating why some people respond to immunotherapy while others do not.

Read more
June 6, 2016

Results from a phase I study conducted in patients with relapsed or refractory metastatic disease revealed that single-agent treatment with the antibody-drug conjugate delivered a powerful blow to tumors bearing delta-like protein 3.

Read more

June 7, 2016

The NLST launched lung cancer screening, and since then, guidelines and recommendations have continued to evolve. Experts discussed rationale for lung screening, practical issues with screening implementation, and the enormous opportunity of addressing tobacco use during an Education Session.

Read more

June 7, 2016

The combination of the checkpoint inhibitor nivolumab with or without the anti–CTLA-4 ipilimumab resulted in durable objective responses for relapsed small cell lung cancer, regardless of platinum sensitivity or tumor PD-L1 expression.

Read more
June 7, 2016

Immune checkpoint inhibitors show promise in combating lung cancer and other malignancies by altering the tumor microenvironment and blocking the immune system evasion that allows cancers to grow and proliferate.

Read more
June 7, 2016

Immunotherapy with CD19+ chimeric antigen receptor T cells made up of a defined 1:1 ratio of CD8+ and CD4+ resulted in a durable complete response.

Read more